Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation

被引:40
作者
Menéndez, R [1 ]
Fraga, V [1 ]
Amor, AM [1 ]
González, RM [1 ]
Más, R [1 ]
机构
[1] Natl Ctr Sci Res, Dept Pharmacol, Ctr Natl Prod, Havana 6880, Cuba
关键词
policosanol; lipoprotein fractions; lipid peroxidation; conjugated diene; thiobarbituric acid reactive substances; lysine-amino group reactivity;
D O I
10.1016/S0031-9384(99)00004-9
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Policosanol, a new cholesterol-lowering agent, is a mixture of higher aliphatic primary alcohols isolated from sugar cane (Saccharum officinarum L.) wax, which prevents the onset of espontaneously and experimentally induced atherosclerotic lesions in experimental models. Because the oxidation of low-density lipoprotein (LDL) may play a role in the pathogenesis of atherosclerosis, we investigate the effect of policosanol on copper oxidative susceptibility of rat lipoprotein fractions (VLDL + LDL). Rats fed normal diet were treated with policosanol (250-500 mg/kg/day) for up to 4 weeks. EDTA-free lipoprotein particles were oxidized in a cell-free system by the addition of copper ions, and conjugated dienes generation was monitored by changes of optical density at 234 nm. Thiobarbituric acid-reactive substances (TBARS) content and lysine-amino group reactivity were investigated. After administration, there was no change in cholesterol, triglycerides, and phospholipid content of lipoprotein fractions; however, policosanol significantly prolongs the lag time and reduces the propagation rate of diene generation. Also, policosanol reduces TEARS content and increases lysine reactivity in lipoprotein fractions treated with Cu2+. In conclusion, policosanol, in addition to its cholesterol-lowering effect, has other properties that enables it to reduce the potential of lipoprotein to undergo lipid peroxidation. Such effect can be considered of promissory value in the management of atherosclerosis. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 54 条
[1]   EFFECT OF POLICOSANOL IN LOWERING CHOLESTEROL LEVELS IN PATIENTS WITH TYPE-II HYPERCHOLESTEROLEMIA [J].
ANEIROS, E ;
MAS, R ;
CALDERON, B ;
ILLNAIT, J ;
FERNANDEZ, L ;
CASTANO, G ;
FERNANDEZ, JC .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1995, 56 (02) :176-182
[2]   EFFECT OF SUCCESSIVE DOSE INCREASES OF POLICOSANOL ON THE LIPID PROFILE AND TOLERABILITY OF TREATMENT [J].
ANEIROS, E ;
CALDERON, B ;
MAS, R ;
ILLNAIT, J ;
CASTANO, G ;
FERNANDEZ, L ;
FERNANDEZ, JC .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1993, 54 (03) :304-312
[3]  
Arruzazabala M L, 1994, Biol Res, V27, P205
[4]   MALONDIALDEHYDE AFFECTS THE PHYSICOCHEMICAL AND BIOLOGICAL CHARACTERISTICS OF OXIDIZED LOW-DENSITY-LIPOPROTEIN [J].
AVIRAM, M .
ATHEROSCLEROSIS, 1990, 84 (2-3) :141-143
[5]   MODIFIED FORMS OF LOW-DENSITY-LIPOPROTEIN AND ATHEROSCLEROSIS [J].
AVIRAM, M .
ATHEROSCLEROSIS, 1993, 98 (01) :1-9
[6]   LOVASTATIN INHIBITS LOW-DENSITY-LIPOPROTEIN OXIDATION AND ALTERS ITS FLUIDITY AND UPTAKE BY MACROPHAGES - INVITRO AND INVIVO STUDIES [J].
AVIRAM, M ;
DANKNER, G ;
COGAN, U ;
HOCHGRAF, E ;
BROOK, JG .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (03) :229-235
[7]  
BONNE C, 1989, ARZNEIMITTEL-FORSCH, V39-2, P1242
[8]  
CANETTI M, 1995, ADV THER, V12, P245
[9]   ONE-YEAR STUDY OF THE EFFICACY AND SAFETY OF POLICOSANOL (5 MG TWICE-DAILY) IN THE TREATMENT OF TYPE-II HYPERCHOLESTEROLEMIA [J].
CASTANO, G ;
MAS, R ;
NODARSE, M ;
ILLNAIT, J ;
FERNANDEZ, L ;
FERNANDEZ, JC .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1995, 56 (03) :296-304
[10]  
CHAPMAN MJ, 1980, J LIPID RES, V21, P789